Methods for inhibiting fibrosis in a subject in need thereof
In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
1. A method of protecting a kidney from renal injury in a subject that has undergone, is undergoing, or will undergo treatment with one or more nephrotoxic agents, comprising administering an amount of a MASP-2 inhibitory antibody or antigen-binding fragment thereof effective to prevent or ameliorate the incidence of drug-induced nephropathy.
2. The method according to claim 1 , wherein the MASP-2 inhibitory antibody is monoclonal antibody, or fragment thereof that specifically binds to human MASP-2.
3. The method according to claim 1 , wherein the MASP-2 inhibitory antibody is administered prior to said nephrotoxic agent.
4. The method according to claim 1 , wherein the MASP-2 inhibitory antibody is co-administered simultaneously with said nephrotoxic agent.
5. The method according to claim 1 , wherein the MASP-2 inhibitory antibody is administered after said nephrotoxic agent to treat nephrotoxicity.
6. The method according to claim 1 , wherein the nephrotoxic agent is a therapeutic drug.
7. The method according to claim 1 , wherein the nephrotoxic agent is a radiocontrast dye.
8. The method according to claim 1 , wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody, and a human antibody.
9. The method according to claim 1 , wherein the MASP-2 inhibitory antibody does not substantially inhibit the classical pathway.
10. The method according to claim 1 , wherein the MASP-2 inhibitory antibody inhibits C3b deposition in 90% human serum with an IC 50 of 30 nM or less.
11. The method according to claim 1 , wherein the MASP-2 inhibitory antibody or antigen-binding fragment thereof is administered in an amount effective to improve renal function.
12. The method according to claim 1 , wherein the MASP-2 inhibitory antibody or antigen-binding fragment thereof is administered in an amount effective and for a time sufficient to achieve at least a 20 percent reduction in 24-hour urine protein excretion as compared to baseline 24-hour urine protein excretion in the subject prior to treatment.
13. The method according to claim 2 , wherein the MASP-2 inhibitory monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3 of the amino acid sequence set forth as SEQ ID NO:67 and a light chain variable region comprising CDR-L1, CDR-L2 and CDR-L3 of the amino acid sequence set forth as SEQ ID NO:69.